Clinical Utility of Different Approaches for Detection of Late Pseudoprogression in Glioblastoma With O-(2-[18F]Fluoroethyl)-L-Tyrosine PET. (September 2019)
- Record Type:
- Journal Article
- Title:
- Clinical Utility of Different Approaches for Detection of Late Pseudoprogression in Glioblastoma With O-(2-[18F]Fluoroethyl)-L-Tyrosine PET. (September 2019)
- Main Title:
- Clinical Utility of Different Approaches for Detection of Late Pseudoprogression in Glioblastoma With O-(2-[18F]Fluoroethyl)-L-Tyrosine PET
- Authors:
- Kertels, Olivia
Mihovilovic, Milena I.
Linsenmann, Thomas
Kessler, Almuth F.
Tran-Gia, Johannes
Kircher, Malte
Brumberg, Joachim
Monoranu, Camelia Maria
Samnick, Samuel
Ernestus, Ralf-Ingo
Löhr, Mario
Meyer, Philipp T.
Lapa, Constantin - Abstract:
- Abstract : Purpose: PET/CT using O-(2-[ 18 F]fluoroethyl)-L-tyrosine ( 18 F-FET) has proven valuable in differentiating tumor recurrence and progression from therapy-induced changes. This study aimed to investigate the diagnostic performance of several analytic approaches in the setting of suspected late pseudoprogression (PsP) in glioblastoma multiforme (GBM). Methods: Retrospective analysis of tumor recurrence was performed in 36 patients with histopathologically confirmed GBM and suspicion of recurrence/disease progression more than 12 weeks from cessation of irradiation based on MRI and Response Assessment in Neuro-Oncology working group criteria. For differentiation of late PsP from true tumor recurrence, images were analyzed semiquantitatively employing tumor-to-brain ratios using 5 different approaches for tumor and normal brain reference region definition, respectively. Histopathology and/or clinical and imaging follow-up served as reference. Respective areas under the receiver operating characteristic curve were compared. Results: 18 F-FET PET was able to reliably differentiate PsP from true tumor progression with areas under the receiver operating characteristic curve ranging from 0.80 to 0.88 (all P < 0.01). Irrespective of the approach chosen, the classification differences between the applied methods were not significant (all P > 0.05), albeit approaches focusing on voxels with the highest uptake tended to perform superior. Conclusions: Irrespective of theAbstract : Purpose: PET/CT using O-(2-[ 18 F]fluoroethyl)-L-tyrosine ( 18 F-FET) has proven valuable in differentiating tumor recurrence and progression from therapy-induced changes. This study aimed to investigate the diagnostic performance of several analytic approaches in the setting of suspected late pseudoprogression (PsP) in glioblastoma multiforme (GBM). Methods: Retrospective analysis of tumor recurrence was performed in 36 patients with histopathologically confirmed GBM and suspicion of recurrence/disease progression more than 12 weeks from cessation of irradiation based on MRI and Response Assessment in Neuro-Oncology working group criteria. For differentiation of late PsP from true tumor recurrence, images were analyzed semiquantitatively employing tumor-to-brain ratios using 5 different approaches for tumor and normal brain reference region definition, respectively. Histopathology and/or clinical and imaging follow-up served as reference. Respective areas under the receiver operating characteristic curve were compared. Results: 18 F-FET PET was able to reliably differentiate PsP from true tumor progression with areas under the receiver operating characteristic curve ranging from 0.80 to 0.88 (all P < 0.01). Irrespective of the approach chosen, the classification differences between the applied methods were not significant (all P > 0.05), albeit approaches focusing on voxels with the highest uptake tended to perform superior. Conclusions: Irrespective of the analytical approach, 18 F-FET PET is a robust tool for detection of late PsP with only minor differences between different analytical approaches. However, methodological standardization and harmonization are needed to ensure comparability between different centers. Abstract : Supplemental digital content is available in the text. … (more)
- Is Part Of:
- Clinical nuclear medicine. Volume 44:Number 9(2019)
- Journal:
- Clinical nuclear medicine
- Issue:
- Volume 44:Number 9(2019)
- Issue Display:
- Volume 44, Issue 9 (2019)
- Year:
- 2019
- Volume:
- 44
- Issue:
- 9
- Issue Sort Value:
- 2019-0044-0009-0000
- Page Start:
- Page End:
- Publication Date:
- 2019-09
- Subjects:
- FET -- glioma -- PET -- region of interest -- volume of interest
Nuclear medicine -- Periodicals
Radioisotope scanning -- Periodicals
Nuclear Medicine -- Periodicals
616.07575 - Journal URLs:
- http://gateway.ovid.com/ovidweb.cgi?T=JS&MODE=ovid&NEWS=n&PAGE=toc&D=ovft&AN=00003072-000000000-00000 ↗
http://journals.lww.com/nuclearmed/pages/default.aspx ↗
http://journals.lww.com ↗ - DOI:
- 10.1097/RLU.0000000000002652 ↗
- Languages:
- English
- ISSNs:
- 0363-9762
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3286.314000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 14206.xml